

Spain) for their collaboration, suggestions and professional support.

References

1. Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and *Helicobacter pylori* infection: a systematic review. *Obstet Gynecol.* 2007;110:695–703. <http://dx.doi.org/10.1097/01.AOG.0000278571.93861.26>.
2. Ng QX, Venkatanarayanan N, De Deyn MLZQ, Ho CYX, Mo Y, Yeo WS. A meta-analysis of the association between *Helicobacter pylori* (H. pylori) infection and hyperemesis gravidarum. *Helicobacter.* 2018;23:e12455. <http://dx.doi.org/10.1111/hel.12455>.
3. Dodds L, Fell DB, Joseph AL, Allen VM, Butler B. Outcomes of pregnancies complicated by hyperemesis gravidarum. *Obstet Gynecol.* 2006;107:285–92. <http://dx.doi.org/10.1097/01.AOG.0000195060.22832.cd>.
4. Miquel-Leiz-Zapatero A, Alba-Rubio C, Domingo-García D, Cantón R, Gómez-García de la Pedrosa E, Aznar-Cano E, et al. First national survey of the diagnosis of *Helicobacter pylori* infection in Clinical Microbiology Laboratories in Spain. *Enferm Infecc Microbiol Clin.* 2020;38:410–6. <http://dx.doi.org/10.1016/j.eimc.2019.11.008>.
5. Mansour GM, Nashaat EH. Role of *Helicobacter pylori* in the pathogenesis of hyperemesis gravidarum. *Arch Gynecol Obstet.* 2011;284:843–7. <http://dx.doi.org/10.1007/s00404-010-1759-8>.
6. Zhan Y, Si M, Li M, Jiang Y. The risk of *Helicobacter pylori* infection for adverse pregnancy outcomes: a systematic review and meta-analysis. *Helicobacter.* 2019;24:e12562. <http://dx.doi.org/10.1111/hel.12562>.
7. Gisbert JP, Santander C. Protocolo diagnóstico y tratamiento de la infección por *Helicobacter pylori*. *Medicine.* 2016;12:96–100. <http://dx.doi.org/10.1016/j.med.2016.01.015>.
8. Mentis A, Lehours P, Mégraud F. Epidemiology and diagnosis of *Helicobacter pylori* infection. *Helicobacter.* 2015;20 Suppl 1:1–7. <http://dx.doi.org/10.1111/hel.12250>.
9. Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of *Helicobacter pylori* in special patient populations. *Pharmacotherapy.* 2019;39:1012–22. <http://dx.doi.org/10.1002/phar.2318>.
10. Andersen JT, Petersen M, Jimenez-Solem E, Broedbaek K, Andersen NL, Torp-Pedersen C, et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. *PLoS One.* 2013;8:e53327. <http://dx.doi.org/10.1371/journal.pone.0053327>.

Carlos Santiago Piñel Pérez()^{a,c,*},
María José Gómez-Roso Jareño^{a,c}, Ana Belén García García^b,
Juan José López Galián^{a,c}

^a Servicio de Obstetricia y Ginecología, Hospital Quirónsalud San José, Madrid, Spain

^b Servicio de Microbiología Clínica, Hospital Quirónsalud San José/Rúber Juan Bravo, Madrid, Spain

^c Universidad Europea, Madrid, Spain

* Corresponding author.

E-mail address: carlos.s.pinel@gmail.com (C.S. Piñel Pérez()).

<https://doi.org/10.1016/j.eimc.2021.11.006>

2529-993X/ © 2021 Published by Elsevier España, S.L.U.

on behalf of Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.

Pseudomonas monteilii nosocomial meningitis in a patient with an intraventricular catheter[☆]



Meningitis nosocomial por *Pseudomonas monteilii* en paciente portador de catéter intraventricular

A 78-year-old male was admitted to our hospital with an extra-axial space-occupying lesion suggestive of posterior fossa meningioma, which was later confirmed by nuclear magnetic resonance. Surgery was performed to remove the meningioma and to insert an external ventricular drain to remove excess cerebrospinal fluid (CSF) due to developing secondary hydrocephalus, with subsequent admission to the intensive care unit (ICU).

On day 13 in the ICU, the device was changed after the first device malfunctioned due to the presence of a clot blocking the ventricular portion of the catheter. On day 26, the patient experienced an accelerated decline in neurological function with a blood-like fluid observed in the drain, which was sent for microbiological study. Empirical antibiotic therapy was initiated with meropenem and linezolid.

Biochemistry testing of the fluid suggested a bacterial infection due to the presence of pleocytosis (1320 cells/ml), with 90% polymorphonuclear lymphocytes, low glucose levels (0.2 g/l) and high protein (1.5 g/l) and lactic acid (1.1 g/dl) levels.

A gram stain showed abundant polymorphonuclear leukocytes and gram-negative rods of variable length with no specific morphology. In view of these findings, it was decided to perform a molecular study using multiplex PCR (FilmArray®, BCID panel, bioMérieux), based on the recommendations of Micó et al.,¹ which was negative. Subsequently, a sample was cultured on blood agar, MacConkey agar and chocolate agar and incubated at 37 °C in aerobic conditions and 5% CO₂, respectively.

After 18 hours, growth in pure culture of non-pigmented mucoid colonies was observed on all three media (Fig. 1). The oxidase test was positive. The isolate was identified as *Pseudomonas fluorescens/putida* (99.9% probability) using a MicroScan Combo Panel, Type 71 (Beckman-Coulter, USA). It demonstrated sensitivity to standard doses of: meropenem, amikacin, tobramycin and colistin, and sensitivity with increased exposure to: piperacillin, cefazidime, cefepime, ciprofloxacin and imipenem, based on EUCAST criteria.² Duplicate mass spectrometry (Microflex LT, Bruker Daltonics, USA) identified the isolate as *Pseudomonas monteilii*, with values of 2.25 and 2.10 using matrix only and values of 2.34 and 2.19 with pre-treatment with formic acid.

The final diagnosis was meningoencephalitis caused by *P. monteilii* as a result of infection of the drainage device and treatment was changed to ceftazidime, resulting in a rapid clinical improvement, which was confirmed by negative CSF culture results at 72 h.

The genus *Pseudomonas* is divided into three phylogenetic lineages and at least 19 groups and sub-groups. One of the most relevant groups is the *Pseudomonas putida* group, which comprises up to 15 strains, including *P. monteilii*,³ which was first described in 1997.⁴ Phenotypically it easily fits into this group based on Pickett's and Gilardi's identification schemes,^{5,6} falling into the fluorescent group of non-fermenting gram-negative bacilli (GNB), together with *Pseudomonas aeruginosa* and *Pseudomonas fluorescens*. This phenotypic characterisation is still valid, despite the reclassification of *Pseudomonas* based on RNA/DNA homology studies and 16S rRNA gene sequencing-based characterisation.⁷ Also, per routine clinical laboratory practices, *P. monteilii* can be quickly and safely identified using mass spectrometry.⁸ *P. monteilii* is an environmental microorganism in healthcare settings and is often isolated from sink, tap and shower surfaces.⁹ In this context, it must also be considered as a potential pathogen and, as such, it has also been cultured from clinical specimens such as bronchial aspirates, urine, stool, bile and blood.⁴ Nevertheless, its role as a cause of central nervous system (CNS) infections has been rarely reported. In addition,

[☆] Please cite this article as: Toledo H, Martín-Gutiérrez G, Lepe JA. Meningitis nosocomial por *Pseudomonas monteilii* en paciente portador de catéter intraventricular. *Enferm Infecc Microbiol Clin.* 2022;**40**:92–93.



Fig. 1. *P. monteilii* colonies cultured on Columbia agar under aerobic conditions for 24 h. Colonies are white, shiny and mucoid.

tion, evidence of infection is not clearly demonstrated in many of the cases described and this could suggest that *P. monteilii* may have low pathogenicity, act as a coloniser and only be a source of infection in critically ill or immunocompromised patients or those who have biomedical devices.¹⁰

Conclusions

Based on the above, the growth of *P. monteilii* on culture media was associated with a nosocomial infection of the external drain valve, either due to colonisation from the patient's skin or handling of the device by healthcare staff, with this acting as a portal of entry for this microorganism into the ventricular fluid.

Funding

Guillermo Martín Gutiérrez has a Juan Rodés clinical research contract (JR19/00039) from Instituto de Salud Carlos III, Ministry of Economy and Competitiveness (Ministerio de Economía y Competitividad), and also an Action B - Clinical Researchers (Acción B Clínicos Investigadores) contract (B-0006-2019) for promoting research activities within Clinical Management Units of the Andalusian Health Service (Servicio Andaluz de Salud) 2019, Department of Health and Families (Consejería de Salud y Familias).

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

1. Micó M, Navarro F, de Miniác D, González Y, Brell A, López C, et al. Efficacy of the filmarray blood culture identification panel for direct molecular diagnosis of infectious diseases from samples other than blood. *J Med Microbiol*. 2015;64:1481–8. <http://dx.doi.org/10.1099/jmm.0.000180>.
2. EUCAST. <http://www.eucast.org>, 2020.
3. Gomila M, Peña A, Mulet M, Lalucat J, García-Valdés E. Phylogenomics and systematics in *Pseudomonas*. *Front Microbiol*. 2015;6:214. <http://dx.doi.org/10.3389/fmicb.2015.00214>.
4. Elomari M, Coroler L, Verhille S, Izard D, Leclerc H. *Pseudomonas monteilii* sp. nov., isolated from clinical specimens. *Int J Syst Bacteriol*. 1997;47:846–52. <http://dx.doi.org/10.1099/00207713-47-3-846>.
5. Pickett MJ, Pedersen MM. Characterization of saccharolytic nonfermentative bacteria associated with man. *Can J Microbiol*. 1970;16:351–62. <http://dx.doi.org/10.1139/m70-062>.
6. Gilardi GL. Characterization of *Pseudomonas* species isolated from clinical specimens. *Appl Microbiol*. 1971;21:414–9. <http://dx.doi.org/10.1128/aem.21.3.414-419.1971>.
7. Ogura K, Shimada K, Miyoshi-Akiyama T. A multilocus sequence typing scheme of *Pseudomonas putida* for clinical and environmental isolates. *Sci Rep*. 2019;9. <http://dx.doi.org/10.1038/s41598-019-50299-6>.
8. Timperio AM, Gorrasí S, Zolla L, Fenice M. Evaluation of MALDI-TOF mass spectrometry and MALDI BioTyper in comparison to 16S rDNA sequencing for the identification of bacteria isolated from Arctic sea water. *PLoS One*. 2017;12. <http://dx.doi.org/10.1371/journal.pone.0181860>.
9. De Abreu PM, Farias PG, Paiva GS, Almeida AM, Morais PV. Persistence of microbial communities including *Pseudomonas aeruginosa* in a hospital environment: a potential health hazard. *BMC Microbiol*. 2014;14:118. <http://dx.doi.org/10.1186/1471-2180-14-118>.
10. Scotta C, Juan C, Cabot G, Oliver A, Lalucat J, Bennasar A, et al. Environmental microbiota represents a natural reservoir for dissemination of clinically relevant metallo- β -lactamases. *Antimicrob Agents Chemother*. 2011;55:5376–9. <http://dx.doi.org/10.1128/AAC.00716-11>.

Héctor Toledo, Guillermo Martín-Gutiérrez*, José Antonio Lepe

Unidad de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, Sevilla, Spain

* Corresponding author.

E-mail address: gmartin-ibis@us.es (G. Martín-Gutiérrez).

<https://doi.org/10.1016/j.eimce.2021.11.004>

2529-993X/ © 2021 Published by Elsevier España, S.L.U.

on behalf of Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.

Varicella monoarthritis in an immunocompetent woman



Monoartritis varicelosa en una mujer inmunocompetente

Dear Editor,

A woman in her early 30s with no relevant medical record came to A&E with a 24-h history of a fever (37.8 °C) and generalized pruritic cutaneous lesions. She presented with vesicles and erythematous papules, some scabby after recent scratching, distributed in torso and extremities. She also mentioned arthralgia in her right knee associated with a discrete swelling without erythema or ecchymosis, which caused her functional impotence. She had no history of previous traumatism or arthritis in the knee. Weight bearing X-ray of the knees revealed an increase in intra-articular fluid and volume of soft tissue.

Peripheral white blood count showed $6.9 \times 10^6/\mu\text{L}$ leukocytes [normal values: $3.9\text{--}10.2 \times 10^6/\mu\text{L}$], with $4.56 \times 10^6/\mu\text{L}$ neutrophils, $1.4 \times 10^6/\mu\text{L}$ lymphocytes, $12.4 \times 10^6/\mu\text{L}$ monocytes—slightly high—[$2.0\text{--}9.5 \times 10^6/\mu\text{L}$], $1.1 \times 10^6/\mu\text{L}$ eosinophils and $0.0 \times 10^6/\mu\text{L}$ basophiles. Hepatic enzymes were increased, with AST and ALT values of 121 IU/L [0–40 IU/L] and 187 IU/L [0–35 IU/L] respectively, and a GGT of 254 IU/L [0–38 IU/L] and LDH of 560 IU/L [100–190 UI/L]. RCP had risen to 35.1 mg/L [0–5 mg/L].

Enquiring about her epidemiological environment, her stepson had at that moment the chickenpox. She did not recall contracting it as a child. Suspecting a VZV primary infection with a post-exanthematous arthritis, she started treatment with acyclovir (800 mg IV/4 h) and NSAIDs (dexketoprofen and acetaminophen).

Serology for several microorganisms returned positive IgG for Parvovirus, measles and Herpes simplex virus (HSV) 1/2 whereas their respective IgM were all negative. Both IgM and IgG for HSV,